You are here

Alnylam

Alnylam clears phase 2 test for Regeneron-partnered nephropathy med, as it looks to play catch-up against Calliditas

Fierce Biotech

Tue, 08/30/22 - 11:48 am

immunoglobin A nephropathy

clinical trials

Alnylam drug succeeds in heart study, setting stage for FDA filing and showdown with Pfizer

MedCity News

Thu, 08/4/22 - 11:09 am

Alnylam reveals longer wait for anticipated drug trial results

BioPharma Dive

Thu, 07/28/22 - 12:25 pm

clinical trials

Alnylam ratchets up Pfizer, Moderna infringement fight on same day it scored new patent

Fierce Pharma

Wed, 07/13/22 - 08:18 pm

Moderna Therapeutics

Alnylam wins FDA approval of rare disease drug in step toward profitability

BioPharma Dive

Tue, 06/14/22 - 11:14 am

hATTR amyloidosis

With Alzheimer's in its sights, Alnylam shares data on getting siRNA to targets beyond the liver

Fierce Pharma

Tue, 06/7/22 - 09:59 am

Alzheimer's disease

drug development

Pfizer shoots back at Alnylam's claims in high-stakes COVID-19 vaccine patent case

Fierce Pharma

Thu, 06/2/22 - 10:21 am

Alnylam shoots for the heart

EP Vantage

Thu, 05/19/22 - 10:16 am

ATTR amyloidosis

How a surprise finding made an Alnylam study one of biotech’s most ‘polarizing’ trials

BioPharma Dive

Tue, 04/26/22 - 10:31 am

clinical trials

transthyretin amyloid cardiomyopathy

Alnylam's potential fourth RNAi approval delayed three months, but impact likely to be 'modest'

Endpoints

Mon, 04/4/22 - 11:08 pm

The biggest launches of 2022: a reboot

EP Vantage

Mon, 02/14/22 - 10:48 am

Mirati Therapeutics

Bristol Myers Squibb

deucravacitinib

SFNP 2022 – Alnylam takes heart from its Onpattro follow-on

EP Vantage

Tue, 01/25/22 - 10:41 am

hereditary ATTR amyloidosis

Alnylam, awaiting key study data, builds case for its next rare disease drug

BioPharma Dive

Sat, 01/22/22 - 02:12 pm

7 drugs likely to hit $1B in annual revenue in the next 5 years

Beckers Hospital Review

Thu, 01/13/22 - 07:31 am

Mirati Therapeutics

Where will Novartis spend the $21B from Roche stake sale? Alnylam buyout could be one: report

Fierce Pharma

Thu, 11/18/21 - 10:50 am

What Novartis could buy with its windfall

EP Vantage

Fri, 11/5/21 - 09:40 am

Aurinia Pharmaceuticals

Alnylam Announces Planned CEO Leadership Transition

Yahoo Finance

Thu, 10/28/21 - 10:42 am

John Maraganore

Dicerna can’t catch up with Alnylam

EP Vantage

Mon, 08/9/21 - 10:50 am

Primary Hyperoxaluria

Alnylam's Study on Renal Treatment Shows Promising Results In Phase III Trial

BioSpace

Mon, 08/2/21 - 11:06 am

clinical trials

A 'springboard' to the future: Genentech, Sanofi and Alnylam execs sound off on pharma's evolving back-to-work plans

Fierce Pharma

Wed, 05/26/21 - 12:05 am

human resources

Pages